Ver-A-T1D
A randomised, double-blind, placebo controlled, parallel group, multi-centre trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigating the effect of Verapamil SR on preservation of beta-cell function.
Background
This clinical study with Verapamil has the objective of examining the protective function of Verapamil on the pancreas in adults who have recently been diagnosed with Type I Diabetes (T1D) in order to prevent the sickness process of T1D from the onset.
This known blood pressure lowering drug has been shown recently to protect and strengthen beta cells and slow down beta cell destruction in T1D. The trial will include 120 patients aged between 18 and 45 years, taking tablets for 1 year.
Funding
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115797 (INNODIA) and No 945268 (INNODIA HARVEST).
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme, The European Federation of Pharmaceutical Industries and Association (EFPIA), Juvenile Diabetes Research Foundation (JDRF) and The Leona M. and Harry B. Helmsley Charitable Trust.
Information
| Chief Investigator(s) | |
|---|---|
| Sponsor | Medical University of Graz |
| Website | https://www.innodia.eu/trials/ |
Key facts
| Start date | 8 Feb 2021 |
|---|---|
| End date | 8 Feb 2023 |
| Status |
|
